[untitled]
1 comments
Enlivex's concurrent RAIN token acquisition and share repurchase program represents one of the more direct examples to date regarding convergence between biotechnology and crypto treasury types. Enlivex is betting that its immunotherapy development pipeline, along with its ownership interest in decentralized prediction markets, will produce long-term value. Keep an eye on it.